51491-68-0Relevant articles and documents
RhIII-Catalyzed C-H (Het)arylation/Vinylation of N-2,6-Difluoroaryl Acrylamides
Wang, Huai-Wei,Qiao, Yu-Han,Wu, Jia-Xue,Wang, Qiu-Ping,Tian, Meng-Xin,Li, Yong-Fei,Yao, Qing-Xia,Li, Da-Cheng,Dou, Jian-Min,Lu, Yi
, p. 656 - 662 (2021)
RhIII-catalyzed sp2 C-H cross-coupling of acrylamides with organoboron reactants has been accomplished using a commercially available N-2,6-difluoroaryl acrylamide auxiliary. A broad range of aryl and vinyl boronates as well as a variety of heterocyclic boronates with strong coordinating ability can serve as the coupling partners. This transformation proceeds under moderate reaction conditions with excellent functional group tolerance and high regioselectivity.
Photoredox Cyclization of N-Arylacrylamides for Synthesis of Dihydroquinolinones
Liu, Zhaosheng,Zhong, Shuai,Ji, Xiaochen,Deng, Guo-Jun,Huang, Huawen
supporting information, p. 349 - 353 (2021/12/27)
Metal- and additive-free photoredox cyclization of N-arylacrylamides is herein reported that provides a concise access to the formation of dihydroquinolinones. In this protocol, sustainable visible light was used as the energy source, and the organic light-emitting molecule 4CzIPN served as the efficient photocatalyst. This reaction system features exclusive 6-endo-trig cyclization selectivity with a generally good yield of a range of functionalized dihydroquinolinones and dihydrobenzoquinolinones. Mechanistical studies reveal the feasibility of both 1,3-H shift and intersystem crossing of the diradical intermediate.
THERAPEUTIC COMPOUNDS AND METHODS OF USE
-
Paragraph 0646; 0647; 0648, (2021/05/21)
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.